Purification of dengue virus like particle from insect cell culture
Bạn đang xem bản rút gọn của tài liệu. Xem và tải ngay bản đầy đủ của tài liệu tại đây (2.01 MB, 57 trang )
:53–9.
18. Miller N (2010). Recent progress in dengue vaccine research and development. Curr
Opin Mol Ther. 2010 Feb;12(1):31-8.
19. Mukhopadhyay S, Kuhn RJ, Rossmann MG (2005). A structural perspective of the
flavivirus life cycle. Nat Rev Microbiol. 2005 Jan; 3(1):13-22.
20. Murphy BR, Whitehead SS (2011). Immune response to dengue virus and prospects
for a vaccine. Annu Rev Immunol 2011; 29: 587–619.
21. Normile D. Tropical medicine (2013). Surprising new dengue virus throws a spanner
in disease control efforts. Science 2013;342(6157):415.
22. Perera R, Kuhn RJ (2008). Structural proteomics of dengue virus. Curr Opin
Microbiol 2008; 11:369–77.
23. Rodenhuis-Zybert IA, van der Schaar HM, da Silva Voorham JM, van der EndeMetselaar H, Lei HY, Wilschut J, et al (2010). Immature dengue virus: a veiled
pathogen. PLoS Pathog 2010; 6:e1000718.
24. Rogers, D. J., Wilson, A. J., Hay, S. I. & Graham, A. J. (2006). The global
distribution of yellow fever and dengue. Adv. Parasitol. 62, 181–220 (2006)
25. Simmons, C. P., Farrar, J. J., van Vinh Chau, N. & Wills, B (2012). Dengue. N. Engl.
J. Med. 366, 1423–1432 (2012).
26. Singhasivanon P1, Jacobson J. (2009). Dengue is a major global health problem. J
Clin Virol. 2009 Oct;46 Suppl 2:S1-2.
27. Solomonides, Tony (2010). Healthgrid applications and core technologies:
proceedings of HealthGrid 2010 ([Online-Ausg.]. ed.). Amsterdam: IOS Press. p. 235.
ISBN 978-1-60750-582-2.
28. Staropoli I, Frenkiel MP, Megret F, et al (1997) Affinity-purified dengue-2 virus
envelope glycoprotein induces neutralizing antibodies and protective immunity in mice.
Vaccine 1997, 15:1946-54.
39
29. Yorgo Modis, Steven Ogata, David Clements, Stephen C. Harrison (2004). Structure
of the dengue virus envelope protein after membrane fusion. Nature 427, 313-319.
30. Zhang Y, Zhang W, Ogata S, Clements D, Strauss JH, Baker TS,Kuhn RJ, Rossmann
MG (2004) Conformational changes of the flavivirus E glycoprotein. Structure
12:1607-1618.
31. Zhang, S., Liang, M., Gu, W., Li, C., Miao, F., Wang, X., Jin, C., Zhang, L., Zhang,
F., Zhang, Q., Jiang, L., Li, M., Li, D (2011). Vaccination with dengue virus-like
particles induces humoral and cellular immune responses in mice. Virol. J. 8, 333.
Internet resource
1. Dengue vaccine Initiative (2016). ( ) (Accessed 2016)
2. Dengue Virus Net (2016) ( )
(Accessed 2016)
3. Dengue Virus Net (2016). ( />(Accessed 2016)
4. Nature Education (2014). (Accessed 2014)
5. UKHealthCentre (2016). ( ) (Accessed 27 August 2016)
6. WHO. Dengue and dengue haemorrhagic fever. Factsheet No 117, revised May 2008.
Geneva, World Health Organization, 2008.
( ) (Acceessed May 2008)
7. WHO. Dengue Guidelines for Diagnosis, Treatment, Prevention and Control. Geneva:
World Health Organization (2009).
( )
(Accessed Feb 24, 2014).
40
APPENDIX
1. 0.5M Tris-HCl (100ml)
• Tris: 6.05g
• Dissolve in 70ml distilled water
• Adjust the pH to 6.8 with HCl and make up to 100ml
• Store at 4°C
2. 1.5M Tris-HCl 100ml)
• 18.15g
• Dissolve in 70ml distilled water
• Adjust the pH to 8.8 with HCl and make up to 100ml
• Store at 4°C
3. 10% Amino persulphate (10% APS) (1ml)
• Ammonium persulphate: 100mg
• Dissolve in 70ml distilled water (prepare fresh everytime)
4. 10% resolving (2gel)
• 30% Bis-Acrylamide: 6.075ml
• 1.5M Tris-HCl (pH=8.8): 4.95ml
• 10% SDS: 150µl
• DI water: 3.75ml
• TEMED: 7.5 µl
• 10% APS: 75 µl
5. 10% SDS (100ml)
• SDS: 10g
•
O : 90ml
41
6. 12% resolving
• 30% Bis-Acrylamide: 5.94ml
• 1.5M Tris-HCl (pH=8.8): 3.75ml
• 10% SDS: 150µl
• DI water: 5.085ml
• TEMED: 7.5 µl
• 10% APS: 75 µl
7. 4% stocking
• 30% Bis-Acrylamide: 0.99ml
• 1.5M Tris-HCl (pH=8.8): 1.89ml
• 10% SDS: 75µl
• DI water: 4.5ml
• TEMED: 7.5 µl
• 10% APS: 37.5 µl
8. Binding buffer (1L)
Make 20mM sodium phosphate
• 0.2M di-sodium phosphate (
.2
) (100ml)
di-sodium phosphate : 3.56g
Dissolve in 100ml distilled water
• 0.2M
.
O (100ml)
mono-sodium phosphate : 2.76g
Dissolve in 100ml distilled water
• Adjust pH by mixing mono-sodium phosphate and di-sodium phosphate
• Mix 100ml Sodium phosphate and 900ml distilled water
42
9. Blocking buffer 3% BSA (50ml)
• BSA: 1.5g
• Add 30ml PBST
• Mix well up to 50ml
10. Blocking buffer 5% skim milk (50 ml)
• Skim milk: 2.5g
• Add PBST and mix well up to 50ml
11. Destanining Solution (500ml)
• Methanol: 200ml
• Acetic acid: 35ml
• Up to 500ml with distilled water
12. Developeing buffer (5ml) (AP conjuagate substrate kit)
• Development buffer: 200ml
• Reagent A: 50µl
• Reagent B: 50µl
• DI water: 4.7ml
13. Developing solution (100ml)
• 500µl of 1% citric (0.01g/1ml DI)
• 50µl 37% formaldehyde
• Up to 100ml with DI water
14. Elution buffer (1L)
Make 20mM sodium phosphate
• 0.2M di-sodium phosphate (
.2
di-sodium phosphate : 3.56g
Dissolve in 100ml distilled water
43
) (100ml)
• 0.2M
.
O (100ml)
mono-sodium phosphate : 2.76g
Dissolve in 100ml distilled water
• Adjust pH by mixing mono-sodium phosphate and di-sodium phosphate
• Mix 100ml Sodium phosphate and 900ml distilled water
Mix 100ml Sodium phosphate with 2M NaCl and up to 1L with distilled water
15. PBS 10X (250ml, pH=7.4)
• NaCl: 20g
• KCl: 0.5g
•
: 0.6g
•
: 3.6g
• Dissolve in 100ml distilled water and adjust pH by NaOH up to 7.4
16. PBST (500ml)
• 1X PBS: 497.5ml
• 0.5% Tween 20: 2.5ml
17. Running buffer 10X (500ml, pH=8.3)
• 250mM Tris: 15.15g
• 1.92M glycerin: 72g
• 1% SDS: 2.5g
• Dissolve in distilled water and up to 500ml
18. Silver nitrate solution
• 0.8g Ag
/ 4ml DI water
• 0.36% NaOH: 21ml
•
OH: 1.4ml
• Up to 100ml with DI water
44
19. Staining solution (500ml)
• Commassie blue: 0.125g
• Methanol: 200ml
• Acetic acid: 35ml
• Adjust volume by distilled water
20. Transfer buffer (500ml)
• Methanol: 100ml
• Tris base: 7.21g
• Glycine: 1.52g
• Up to 500ml with distilled water
45
